资讯

Targeted Oncology21 小时
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
In an interview with Targeted Oncology, C. Ola Langren, MD, discussed the continuing impact of the groundbreaking FDA ODAC ...